17,313
Total Claims
$1.5M
Drug Cost
1,052
Beneficiaries
$1,431
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
+1%
Cost per patient vs peers
$1,431 vs $1,411 avg
-5%
Brand preference vs peers
10.1% vs 10.6% avg
Brand vs Generic
90% generic
Brand: 1,744 claims · $1.2M
Generic: 15,443 claims · $312K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 197 | $197K |
| Semaglutide | 144 | $165K |
| Sitagliptin Phosphate | 88 | $81K |
| Empagliflozin | 59 | $77K |
| Fluticasone/Umeclidin/Vilanter | 75 | $69K |
| Dapagliflozin Propanediol | 55 | $58K |
| Dulaglutide | 36 | $48K |
| Insulin Glargine,hum.Rec.Anlog | 43 | $34K |
| Rivaroxaban | 30 | $33K |
| Tirzepatide | 28 | $32K |
| Linagliptin | 30 | $29K |
| Insulin Glargine,hum.Rec.Anlog | 29 | $25K |
| Insulin Aspart | 34 | $24K |
| Linaclotide | 17 | $21K |
| Evolocumab | 27 | $20K |
Prescribing Profile
Patient Profile
73
Avg Age
47%
Female
1.11
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About